Analysts expect MEDNAX Inc (NYSE:MD) to report earnings per share (EPS) of $0.99 for the current quarter, according to Zacks Investment Research. Nine analysts have issued estimates for MEDNAX’s earnings. The lowest EPS estimate is $0.89 and the highest is $1.09. MEDNAX reported earnings per share of $0.87 in the same quarter last year, which would indicate a positive year-over-year growth rate of 13.8%. The business is expected to report its next quarterly earnings results on Wednesday, November 7th.
According to Zacks, analysts expect that MEDNAX will report full-year earnings of $4.01 per share for the current year, with EPS estimates ranging from $3.89 to $4.21. For the next fiscal year, analysts forecast that the firm will post earnings of $4.35 per share, with EPS estimates ranging from $4.10 to $4.63. Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover MEDNAX.
MEDNAX (NYSE:MD) last announced its quarterly earnings data on Thursday, August 2nd. The company reported $1.07 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.07. MEDNAX had a net margin of 9.59% and a return on equity of 10.42%. The company had revenue of $915.90 million for the quarter, compared to the consensus estimate of $911.77 million. During the same period in the prior year, the firm posted $0.85 EPS. MEDNAX’s revenue for the quarter was up 8.6% on a year-over-year basis.
Several analysts recently commented on the stock. Leerink Swann assumed coverage on shares of MEDNAX in a research report on Thursday, July 12th. They set a “market perform” rating and a $50.00 price objective on the stock. Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating in a research report on Tuesday, August 7th. ValuEngine raised shares of MEDNAX from a “strong sell” rating to a “sell” rating in a research report on Friday, August 3rd. Credit Suisse Group raised shares of MEDNAX from a “neutral” rating to an “outperform” rating and raised their price target for the company from $47.00 to $55.00 in a report on Friday, August 3rd. Finally, Stifel Nicolaus set a $47.00 price target on shares of MEDNAX and gave the company a “hold” rating in a report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $54.71.
In other news, SVP Dominic J. Andreano sold 18,000 shares of the stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $46.95, for a total value of $845,100.00. Following the transaction, the senior vice president now owns 24,896 shares in the company, valued at approximately $1,168,867.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Vivian Lopez-Blanco sold 13,942 shares of the stock in a transaction that occurred on Tuesday, June 12th. The stock was sold at an average price of $46.46, for a total transaction of $647,745.32. Following the completion of the transaction, the chief financial officer now owns 100,590 shares in the company, valued at approximately $4,673,411.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 41,958 shares of company stock worth $1,964,860. Insiders own 2.70% of the company’s stock.
Large investors have recently modified their holdings of the company. Fort Washington Investment Advisors Inc. OH lifted its stake in shares of MEDNAX by 55.7% in the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 363,201 shares of the company’s stock worth $15,719,000 after purchasing an additional 130,001 shares during the period. Bank of Montreal Can raised its stake in MEDNAX by 6.8% during the 2nd quarter. Bank of Montreal Can now owns 210,277 shares of the company’s stock worth $9,102,000 after acquiring an additional 13,360 shares during the period. Legal & General Group Plc raised its stake in MEDNAX by 16.4% during the 1st quarter. Legal & General Group Plc now owns 137,616 shares of the company’s stock worth $7,655,000 after acquiring an additional 19,421 shares during the period. Pzena Investment Management LLC raised its stake in MEDNAX by 1.8% during the 2nd quarter. Pzena Investment Management LLC now owns 2,299,800 shares of the company’s stock worth $99,535,000 after acquiring an additional 41,088 shares during the period. Finally, State of Alaska Department of Revenue raised its stake in MEDNAX by 40.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 10,030 shares of the company’s stock worth $434,000 after acquiring an additional 2,870 shares during the period. Hedge funds and other institutional investors own 95.51% of the company’s stock.
MD stock traded down $0.31 during trading on Friday, hitting $47.82. 800,500 shares of the stock traded hands, compared to its average volume of 822,951. MEDNAX has a 1 year low of $40.56 and a 1 year high of $63.04. The company has a market capitalization of $4.43 billion, a price-to-earnings ratio of 15.31, a price-to-earnings-growth ratio of 1.28 and a beta of 0.24. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.52 and a current ratio of 1.52.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
See Also: Google Finance Portfolio Tips and Tricks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.